Literature DB >> 21120947

High-Resolution genomic arrays identify CNVs that phenocopy the chromosome 22q11.2 deletion syndrome.

Tracy Busse1, John M Graham, Gerald Feldman, Juan Perin, Anne Catherwood, Robert Knowlton, Eric F Rappaport, Beverly Emanuel, Deborah A Driscoll, Sulagna C Saitta.   

Abstract

The 22q11 Deletion Syndrome includes the overlapping phenotypes of DiGeorge/Velocardiofacial Syndromes, characterized by conotruncal heart defects, cleft palate, thymus, and parathyroid gland dysplasia. The majority (90%) of patients harbor detectable chr22q11.2 deletions, but a genetic etiology for the remainder of patients without a deletion can remain undefined despite major birth defects. We analyzed DNA from eight patients with normal 22q11 FISH studies by high-density single nucleotide polymorphism (SNP) arrays and identified potentially pathogenic copy number variants (CNVs) in four of eight patients. Two patients showed large CNVs in regions of known genomic disorders: one a deletion of distal chr22q11.2 and the other a duplication of chr5q35. A 3-Mb deletion of chr19p13.3 that includes a gene associated with conotruncal heart defects was found in a third patient. Two potentially pathogenic CNVs were found in a fourth patient: a large heterozygous deletion of chr6p24 and a smaller duplication of chr9p24. Our findings support a recent consensus statement advocating chromosomal microarray analysis as a first-line diagnostic approach for patients with multiple congenital anomalies. In patients with phenotypes suggestive of the 22q11.2 syndrome spectrum and normal FISH, microarray analysis can uncover the molecular basis of other genomic disorders whose features overlap those of 22q11.2 deletions.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21120947     DOI: 10.1002/humu.21395

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

1.  Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome.

Authors:  Lisa D Palmer; Nancy J Butcher; Erik Boot; Kathleen A Hodgkinson; Tracy Heung; Eva W C Chow; Alina Guna; T Blaine Crowley; Elaine Zackai; Donna M McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-04       Impact factor: 2.802

2.  Further Evidence of Contrasting Phenotypes Caused by Reciprocal Deletions and Duplications: Duplication of NSD1 Causes Growth Retardation and Microcephaly.

Authors:  J A Rosenfeld; K H Kim; B Angle; R Troxell; J L Gorski; M Westemeyer; M Frydman; Y Senturias; D Earl; B Torchia; R A Schultz; J W Ellison; K Tsuchiya; S Zimmerman; T A Smolarek; B C Ballif; L G Shaffer
Journal:  Mol Syndromol       Date:  2013-01-05

Review 3.  Connecting teratogen-induced congenital heart defects to neural crest cells and their effect on cardiac function.

Authors:  Ganga H Karunamuni; Pei Ma; Shi Gu; Andrew M Rollins; Michael W Jenkins; Michiko Watanabe
Journal:  Birth Defects Res C Embryo Today       Date:  2014-09-15

Review 4.  Proximal variants in CCND2 associated with microcephaly, short stature, and developmental delay: A case series and review of inverse brain growth phenotypes.

Authors:  Filomena Pirozzi; Benson Lee; Nicole Horsley; Deepika D Burkardt; William B Dobyns; John M Graham; Maria L Dentici; Claudia Cesario; Jens Schallner; Joseph Porrmann; Nataliya Di Donato; Pedro A Sanchez-Lara; Ghayda M Mirzaa
Journal:  Am J Med Genet A       Date:  2021-06-04       Impact factor: 2.802

5.  Screening of 22q11.2DS Using Multiplex Ligation-Dependent Probe Amplification as an Alternative Diagnostic Method.

Authors:  Sathiya Maran; Siti Aisyah Faten; Swee-Hua Erin Lim; Kok-Song Lai; Wan Pauzi Wan Ibrahim; Ravindran Ankathil; Siew Hua Gan; Huay Lin Tan
Journal:  Biomed Res Int       Date:  2020-09-28       Impact factor: 3.411

6.  Genotype-phenotype correlation in 22q11.2 deletion syndrome.

Authors:  Elena Michaelovsky; Amos Frisch; Miri Carmel; Miriam Patya; Omer Zarchi; Tamar Green; Lina Basel-Vanagaite; Abraham Weizman; Doron Gothelf
Journal:  BMC Med Genet       Date:  2012-12-17       Impact factor: 2.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.